Yubo International Biotech Ltd (YBGJ) — SEC Filings
Yubo International Biotech Ltd (YBGJ) — 11 SEC filings. Latest: 10-Q (Nov 14, 2025). Includes 6 10-Q, 2 8-K, 2 10-K.
View Yubo International Biotech Ltd on SEC EDGAR
Overview
Yubo International Biotech Ltd (YBGJ) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: Yubo International Biotech Ltd (YBGJ) reported a net loss of $310,152 for the three months ended September 30, 2025, a significant improvement from the $621,053 net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $902,288, compared to $1,628,906 in 202
Sentiment Summary
Across 11 filings, the sentiment breakdown is: 2 bearish, 8 neutral, 1 mixed. The dominant filing sentiment for Yubo International Biotech Ltd is neutral.
Filing Type Overview
Yubo International Biotech Ltd (YBGJ) has filed 6 10-Q, 2 8-K, 2 10-K, 1 8-K/A with the SEC between Apr 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (11)
| Date | Form | Description | Risk |
|---|---|---|---|
| Nov 14, 2025 | 10-Q | Yubo Biotech Narrows Losses Amidst Zero Revenue, Asset Decline | high |
| Aug 13, 2025 | 10-Q | Yubo Biotech's Sales Vanish, Losses Narrow Amidst Asset Decline | high |
| Jul 25, 2025 | 8-K | Yubo International Biotech Ltd. Files 8-K with Material Agreements | medium |
| May 14, 2025 | 10-Q | Yubo Biotech Q1 2025: Assets $119.8M, Net Income $1.2B | medium |
| Mar 31, 2025 | 10-K | Yubo International Biotech Ltd. Files 2024 10-K | low |
| Jan 10, 2025 | 8-K/A | Yubo International Biotech Files 8-K/A Amendment | low |
| Jan 6, 2025 | 8-K | Yubo International Biotech Changes Certifying Accountant | medium |
| Nov 13, 2024 | 10-Q | Yubo International Biotech Ltd. Files Q3 2024 10-Q | low |
| Aug 19, 2024 | 10-Q | Yubo International Biotech Ltd. Files Q2 2024 10-Q | medium |
| May 20, 2024 | 10-Q | Yubo International Biotech Ltd Files Q1 2024 10-Q | medium |
| Apr 12, 2024 | 10-K | Yubo International Biotech Ltd. Files 2023 Annual Report |
Risk Profile
Risk Assessment: Of YBGJ's 10 recent filings, 2 were flagged as high-risk, 5 as medium-risk, and 3 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$310,152 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $10,926 |
| Operating Margin | N/A |
| Total Assets | $953,211 |
| Total Debt | $0 |
Industry Context
Yubo International Biotech operates in the biotechnology sector, which is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. The industry is highly competitive, with companies often relying on substantial funding rounds to advance their pipelines. The current trend involves a focus on specialized therapies and precision medicine, demanding significant investment in innovation and clinical trials.
Top Tags
biotech (5) · SEC Filing (3) · financials (3) · 10-Q (3) · Biotech (2) · China VIE (2) · Zero Revenue (2) · Net Loss (2) · financial-statements (2) · quarterly-report (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue | $0 | For the three and nine months ended September 30, 2025, indicating no sales. |
| Net loss (3 months) | $310,152 | For the three months ended September 30, 2025, a 50% reduction from $621,053 in 2024. |
| Net loss (9 months) | $902,288 | For the nine months ended September 30, 2025, a 44.6% reduction from $1,628,906 in 2024. |
| Total Assets | $953,211 | As of September 30, 2025, a 37.9% decrease from $1,534,832 at December 31, 2024. |
| Total Liabilities | $2,555,316 | As of September 30, 2025, a 47.1% decrease from $4,832,522 at December 31, 2024. |
| Cash | $10,926 | As of September 30, 2025, a slight increase from $7,015 at December 31, 2024. |
| Ordinary shares issued | 50,600,343 | During the nine months ended September 30, 2025, increasing total shares outstanding. |
| Additional Paid in Capital | $2,530,000 | Raised from the issuance of ordinary shares during the nine months ended September 30, 2025. |
| Occupancy expenses (3 months) | $46,920 | For the three months ended September 30, 2025, a significant reduction from $175,646 in 2024. |
| Revenue from sales of products and services | $0 | for the six months ended June 30, 2025, down from $3,488 in 2024, indicating a complete halt in sales. |
| Net loss | $592,136 | for the six months ended June 30, 2025, an improvement from $1,007,853 in 2024, but still substantial. |
| Accumulated Deficit | $7,326,775 | as of June 30, 2025, an increase from $6,660,811 at December 31, 2024, indicating ongoing losses. |
| Advances from related parties (net) | $473,919 | cash provided by financing activities for the six months ended June 30, 2025, crucial for liquidity. |
| Decrease in Total Operating Expenses | 33% | from $882,518 in 2024 to $592,094 in 2025, contributing to the narrowed net loss. |
| Net Income | $1.2B | For the period ending March 31, 2025 |
Frequently Asked Questions
What are the latest SEC filings for Yubo International Biotech Ltd (YBGJ)?
Yubo International Biotech Ltd has 11 recent SEC filings from Apr 2024 to Nov 2025, including 6 10-Q, 2 8-K, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of YBGJ filings?
Across 11 filings, the sentiment breakdown is: 2 bearish, 8 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Yubo International Biotech Ltd SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Yubo International Biotech Ltd (YBGJ) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Yubo International Biotech Ltd?
Key financial highlights from Yubo International Biotech Ltd's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for YBGJ?
The investment thesis for YBGJ includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Yubo International Biotech Ltd?
Executive information for Yubo International Biotech Ltd is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Yubo International Biotech Ltd stock?
Of YBGJ's 10 assessed filings, 2 were flagged high-risk, 5 medium-risk, and 3 low-risk.
What are recent predictions and forward guidance from Yubo International Biotech Ltd?
Forward guidance and predictions for Yubo International Biotech Ltd are extracted from SEC filings as they are enriched.